Cargando…

Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection

BACKGROUND: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Bruce E, Saraiya, Nimit, Poeth, Kaitlin, Schwartz, Rebecca M, Epstein, Marcia E, Honig, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506624/
https://www.ncbi.nlm.nih.gov/pubmed/25885020
http://dx.doi.org/10.1186/s12879-015-0930-z
_version_ 1782381723158315008
author Hirsch, Bruce E
Saraiya, Nimit
Poeth, Kaitlin
Schwartz, Rebecca M
Epstein, Marcia E
Honig, Gerard
author_facet Hirsch, Bruce E
Saraiya, Nimit
Poeth, Kaitlin
Schwartz, Rebecca M
Epstein, Marcia E
Honig, Gerard
author_sort Hirsch, Bruce E
collection PubMed
description BACKGROUND: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience recurrent CDI. Fecal-derived microbiota transplantation (FMT) can ameliorate the underlying dysbiosis and is highly effective for recurrent CDI. Traditional methods of FMT are limited by patient discomfort, risk and inefficient procedures. Many individuals with recurrent CDI have extensive comorbidities and advanced age. Widespread use of FMT requires strategies that are non-invasive, scalable and applicable across healthcare settings. METHODS: A method to facilitate microbiota transfer was developed. Fecal samples were collected and screened for potential pathogens. Bacteria were purified, concentrated, cryopreserved and formulated into multi-layered capsules. Capsules were administered to patients with recurrent CDI, who were then monitored for 90 days. RESULTS: Thirteen women and six men with recurrent CDI were provided with microbiota transfer with orally administered capsules. The procedure was well tolerated. Thirteen individuals responded to a single course. Four patients were cured after a second course. There were 2 failures. The cumulative clinical cure rate of 89% is similar to the rates achieved with reported fecal-derived transplantation procedures. CONCLUSIONS: Recurrent CDI represents a profound dysbiosis and a debilitating chronic disease. Stable cure can be achieved by restoring the gut microbiome with an effective, well-tolerated oral capsule treatment. This strategy of microbiota transfer can be widely applied and is particularly appropriate for frail patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0930-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4506624
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45066242015-07-19 Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection Hirsch, Bruce E Saraiya, Nimit Poeth, Kaitlin Schwartz, Rebecca M Epstein, Marcia E Honig, Gerard BMC Infect Dis Research Article BACKGROUND: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute symptoms, but up to one third of patients later experience recurrent CDI. Fecal-derived microbiota transplantation (FMT) can ameliorate the underlying dysbiosis and is highly effective for recurrent CDI. Traditional methods of FMT are limited by patient discomfort, risk and inefficient procedures. Many individuals with recurrent CDI have extensive comorbidities and advanced age. Widespread use of FMT requires strategies that are non-invasive, scalable and applicable across healthcare settings. METHODS: A method to facilitate microbiota transfer was developed. Fecal samples were collected and screened for potential pathogens. Bacteria were purified, concentrated, cryopreserved and formulated into multi-layered capsules. Capsules were administered to patients with recurrent CDI, who were then monitored for 90 days. RESULTS: Thirteen women and six men with recurrent CDI were provided with microbiota transfer with orally administered capsules. The procedure was well tolerated. Thirteen individuals responded to a single course. Four patients were cured after a second course. There were 2 failures. The cumulative clinical cure rate of 89% is similar to the rates achieved with reported fecal-derived transplantation procedures. CONCLUSIONS: Recurrent CDI represents a profound dysbiosis and a debilitating chronic disease. Stable cure can be achieved by restoring the gut microbiome with an effective, well-tolerated oral capsule treatment. This strategy of microbiota transfer can be widely applied and is particularly appropriate for frail patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0930-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-17 /pmc/articles/PMC4506624/ /pubmed/25885020 http://dx.doi.org/10.1186/s12879-015-0930-z Text en © Hirsch et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hirsch, Bruce E
Saraiya, Nimit
Poeth, Kaitlin
Schwartz, Rebecca M
Epstein, Marcia E
Honig, Gerard
Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
title Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
title_full Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
title_fullStr Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
title_full_unstemmed Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
title_short Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection
title_sort effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent clostridium difficile infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506624/
https://www.ncbi.nlm.nih.gov/pubmed/25885020
http://dx.doi.org/10.1186/s12879-015-0930-z
work_keys_str_mv AT hirschbrucee effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection
AT saraiyanimit effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection
AT poethkaitlin effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection
AT schwartzrebeccam effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection
AT epsteinmarciae effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection
AT honiggerard effectivenessoffecalderivedmicrobiotatransferusingorallyadministeredcapsulesforrecurrentclostridiumdifficileinfection